With the US Food and Drug Administration’s newly broadened emergency use authorization for the Pfizer Inc./BioNTech SE and Moderna, Inc. COVID-19 vaccines in hand, a Centers for Disease Control and Prevention panel voted on 19 November to expand recommended use of the mRNA vaccine booster doses and simplify determinations for eligibility.
The Advisory Committee on Immunization Practices recommended extending the option to get a single booster dose to all individuals ages 18 years and older. In a separate vote, the committee...